Treatment with eribulin mesilate could suppress epithelial-mesenchymal transition (EMT) in tumors of patients with metastatic breast cancer - preliminary report of a prospective

被引：2
|
作者：
Utsumi, T. [1 ]
Hayashi, T. [2 ]
Kobayashi, N. [1 ]
Hikichi, M. [1 ]
Ushimado, K. [1 ]
Ri, Y. [1 ]
Nakano, S. [3 ]
Fujii, K. [3 ]
Ando, T. [3 ]
机构：
[1] Fujita Hlth Univ, Dept Breast Surg, Toyoake, Aichi, Japan
[2] Fujita Hlth Univ, Dept Biochem, Toyoake, Aichi, Japan
[3] Aichi Med Univ, Div Breast & Endocrine Surg, Dept Surg, Nagakute, Aichi, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷
关键词：
D O I：
10.1016/S0959-8049(17)30209-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
246
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [1] Eribulin mesylate (eribulin) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. -First preliminary report of a prospective study
    Utsumi, T.
    Hayashi, T.
    Kobayashi, N.
    Hikichi, M.
    Ushimado, K.
    Ri, Y.
    Nakano, S.
    Fujii, K.
    Ando, T.
    CANCER RESEARCH, 2017, 77
  • [2] Effect of eribulin on epithelial-mesenchymal transition plasticity in metastatic breast cancer: An exploratory, prospective study
    Hayashi, Takanori
    Kobayashi, Naomi
    Ushida, Kaori
    Asai, Naoya
    Nakano, Shogo
    Fujii, Kimihito
    Ando, Takahito
    Utsumi, Toshiaki
    GENES TO CELLS, 2023, 28 (05) : 364 - 373
  • [3] Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states
    Yoshida, T.
    Ozawa, Y.
    Kimura, T.
    Sato, Y.
    Kuznetsov, G.
    Xu, S.
    Uesugi, M.
    Agoulnik, S.
    Taylor, N.
    Funahashi, Y.
    Matsui, J.
    BRITISH JOURNAL OF CANCER, 2014, 110 (06) : 1497 - 1505
  • [4] Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
    T Yoshida
    Y Ozawa
    T Kimura
    Y Sato
    G Kuznetsov
    S Xu
    M Uesugi
    S Agoulnik
    N Taylor
    Y Funahashi
    J Matsui
    British Journal of Cancer, 2014, 110 : 1497 - 1505
  • [5] Epithelial-mesenchymal transition and tumor vascular remodeling in eribulin chemotherapy for breast cancer
    Shinichiro, Kashiwagi
    Asano, Yuka
    Tauchi, Yukie
    Mao, Tokumoto
    Morisaki, Tamami
    Noda, Satoru
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Onoda, Naoyoshi
    Hirakawa, Kosei
    CANCER RESEARCH, 2015, 75
  • [6] Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women
    Lakhtakia, Ritu
    Aljarrah, Adil
    Furrukh, Muhammad
    Ganguly, Shyam S.
    CANCER MICROENVIRONMENT, 2017, 10 (1-3) : 25 - 37
  • [7] Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors
    Akrida, Ioanna
    Mulita, Francesk
    Plachouri, Kerasia-Maria
    Benetatos, Nikolaos
    Maroulis, Ioannis
    Papadaki, Helen
    MEDICAL ONCOLOGY, 2023, 41 (01)
  • [8] Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors
    Ioanna Akrida
    Francesk Mulita
    Kerasia-Maria Plachouri
    Nikolaos Benetatos
    Ioannis Maroulis
    Helen Papadaki
    Medical Oncology, 41
  • [9] Epithelial mesenchymal transition (EMT) phenotype in metastatic and non-metastatic breast cancer
    Lakhtakia, R.
    Al-Jarrah, A.
    Furrukh, M.
    Ganguly, S. S.
    VIRCHOWS ARCHIV, 2017, 471 : S59 - S59
  • [10] Epithelial-Mesenchymal Transition (EMT) Is Not Sufficient for Spontaneous Murine Breast Cancer Metastasis
    Lou, Yuanmei
    Preobrazhenska, Olena
    Keller, Ulrich auf dem
    Sutcliffe, Margaret
    Barclay, Lorena
    McDonald, Paul C.
    Roskelley, Calvin
    Overall, Christopher M.
    Dedhar, Shoukat
    DEVELOPMENTAL DYNAMICS, 2008, 237 (10) : 2755 - 2768
12345